NCT03053089View on ClinicalTrials.gov

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions
Mucopolysaccharidosis I
Interventions
DRUG

AGT-181

Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein

Trial Locations (1)

90035-903

HCPA - Hospital das Clinicas de Porto Alegre, Porto Alegre

Sponsors

Lead Sponsor

ArmaGen, Inc
All Listed Sponsors
lead

ArmaGen, Inc

INDUSTRY